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Abstract 
This review aims at providing insight into the factors that influence quantification of glucose metabolism by 
FDG-PET images in oncology as well as their influence on repeated-measures studies (i.e. treatment response 
assessment), offering improved understanding both for the clinical practice and research. Quantification of 
glucose metabolism by FDG-PET is affected by many factors. Biological factors such as fasted blood glucose 
level, FDG uptake period, FDG distribution and clearance, patient motion (breathing) and patient discomfort 
(stress) all influence quantification. Acquisition parameters should be adjusted to maximize the signal-to-noise 
ratio without posing the patient at a higher than strictly necessary radiation dose. This is especially challenging 
in pharmacokinetic analysis, where the temporal resolution is of significant importance. The literature is 
reviewed on the influence of attenuation correction on parameters for glucose metabolism, the effect of motion, 
metal artefacts and contrast agents on quantification of CT attenuation-corrected images. Reconstruction settings 
(analytical versus iterative reconstruction, post-reconstruction filtering and image matrix size) all potentially 
influence quantification due to artefacts, noise levels and lesion-size dependency. Many region-of-interest 
definitions are available, but increased complexity does not necessarily result in improved performance. 
Different methods for the quantification of the tissue of interest can introduce systematic and random inaccuracy. 
 
Keywords: Fluorodeoxyglucose F18, Positron-Emission Tomography, Pharmacokinetics, Computer-Assisted 
Image Processing, Reference Standards 
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Introduction 
Positron emission tomography (PET, see table 1 for all abbreviations in this paper) using 2-[18F]-2-deoxy-D-
glucose (FDG) is an established imaging modality in oncology [1]. Although in daily practice visual inspection 
of FDG-PET images is used for diagnosis and assessment of response to therapy, it has been shown that (semi-) 
quantitative analysis allows an objective complement to visual interpretation of lesions [2-4]. Results of this 
analysis might be used for individual tailoring of therapy, since increased FDG uptake usually corresponds to a 
dismal course of the disease. Repeated measurements can be used in early response assessment, valuable for 
further individualization of therapy [5]. Generally, lesions are quantified using the standardized uptake value of 
FDG (SUV, i.e. the FDG activity concentration at a single time point normalized to the administered activity 
(AA) and a measure for distribution volume such as bodyweight) and treatment response is assessed by the 
relative change between a baseline and a follow-up scan during the course of therapy (ΔSUV). Although the 
results of the first trials have been published in which the performance of individually tailored therapy based on 
early response to neoadjuvant treatment is investigated [6] and new trials are currently being undertaken, the 
multiple factors influencing the quantification of glucose metabolism by FDG-PET are still under discussion [7-
9]. 
Besides the influence that these factors have on the quantification of parameters of glucose metabolism, a 
variety of factors also influence the reproducibility of these parameters [10, 11]. Quantification of glucose 
metabolism by FDG-PET is not only dependent on biological properties of the disease under investigation, but 
also on methodological aspects of patient preparation, image acquisition, reconstruction, region of interest (ROI) 
definition and methods of parameter computation. To be able to perform multi-centre studies or meta-analysis, 
but also to apply results of studies in clinical practice, the influence of these factors should be minimized by 
standardization. This has led to the development of consensus recommendations by the European Organization 
for Research and Treatment of Cancer (EORTC) [12], the National Cancer Institute (NCI) [13] and the 
Netherlands Society of Nuclear Medicine (NEDPAS) [14]. The Society of Nuclear Medicine has agreed on 
procedure guidelines for tumour imaging but conclude that optimal methods for semiquantitative measurements 
need further elucidation [15]. 
This review aims to give a theoretical background illustrated by up-to-date publications on the influence of 
methodological factors influencing quantification of FDG-PET. It will not merely focus on the semiquantitative 
parameter SUV, but also include fully quantitative parameters such as the glucose metabolic rate (MRglc) and the 
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pharmacokinetic rate constants of 2-compartment model analysis. Hardware issues influencing scanner 
sensitivity, such as detector crystal material, photon energy window, coincidence timing window, detector ring 
diameter and axial length of the field of view (FOV) are not addressed in this review. Several other factors are 
considered outside the scope of this study, these are: methodological errors, such as invalid cross-calibration, 
asynchronous clocks, omission of decay correction for the time period between calibration and start of the PET-
scan, low precision of plasma glucose measurement, failure to measure residual activity concentration of the 
infusion system or paravenous infiltration of FDG and factors inextricably linked to the non-specific targeting of 
FDG (e.g. infection, post-radiotherapy inflammation). 
 
1 Patient preparation and image acquisition 
1.1 Biological factors affecting quantification 
Several biological factors affecting quantification, such as fasted plasma glucose level, uptake period, FDG 
distribution and clearance, patient motion (breathing) and patient discomfort (stress), all deserve attention at the 
time of patient preparation, FDG administration and distribution and image acquisition. 
 
1.1.1 Blood glucose level 
High blood glucose levels, due to a non-fasting state or diabetes mellitus, interfere with FDG uptake in 
malignant lesions. The transmembranous glucose transport facilitators (GLUT), albeit overexpressed in many 
cancers, can be saturated by an excess of unlabeled glucose. This diminishes FDG uptake as glucose and FDG 
both compete for the binding sites of transporters and enzymes, leading to zero-order kinetics. In patients 
without any known form of glucose intolerance it is shown in two consecutive scans that the SUV, using 
bodyweight as a measure of distribution volume, is significantly lower in the loaded state (serum glucose >8.0 
mmol·L-1) in both head and neck cancer (SUVBW=6.9 vs. 4.0, p<0.02) [16] and bronchial carcinoma 
(SUVBW=5.07 vs. 2.84, p<0.001) [17] compared to the fasted state (<6.0 mmol·L-1). In contrast to the reduction 
of tumour uptake, skeletal muscle accumulates more FDG, resulting in blurring of tumour margins and less clear 
localization of lesions [16]. Also Patlak-based net influx rate constants (Ki) of the lesions decreases markedly in 
the glucose loaded state (mean -25%, p<0.05), while MRglc is on average 36% higher. This paradoxical increase 
in MRglc might be due to the fact that the authors assumed the same value for the relative affinity of the 
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biological system to FDG and glucose (‘lumped constant’, LC) in both states to compute MRglc from Ki, which is 
likely untrue [18]. 
The effect of hyperglycaemia has clear impact on visual interpretation of FDG-PET images as it results in a 
reduced detection rate of malignancies [19], but it also has a major effect on quantification. Therefore, 
hyperglycaemia should be a reason to reschedule the procedure. Correction of hyperglycaemia by insulin directly 
prior to the FDG-injection is dissuaded, because hyperinsulinaemia increases the translocation of GLUT4 thereby 
rapidly and efficiently shunting FDG to organs with a high density of insulin receptors (e.g. skeletal and cardiac 
muscles) [19]. When FDG injection is postponed to one hour after insulin administration (up to a serum glucose 
below 8.0 mmol·L-1) in hyperglycaemic diabetic patients, no differences between normoglycemic non-diabetics 
and hyperglycaemic (insulin-corrected) diabetics are found in SUV, using lean body mass as measure for 
distribution volume (SUVLBM), in lungs, liver, muscles, myocardium or suspected pulmonary lesions [20]. 
However, recently a standardized protocol of intravenous insulin at least one hour prior to FDG injection, led to 
an unacceptable biodistribution in 25% of diabetic cancer patients (increased muscle uptake and decrease liver 
uptake). In these patients the interval between insulin and FDG injection was significantly shorter than in the 
patients with a normal biodistribution (65.7 vs. 80.2 min, p<0.01) [21]. Metformin strongly increases the SUV of 
the small and large intestines, potentially decreasing the detection sensitivity for malignant lesions, but the 
influence on lesion quantification is not described [22]. To prevent hyperglycaemia in non-diabetic patients, 
guidelines [12-14] recommend that patients should have fasted at least 4 hours, but preferably 6 hours before 
administration of FDG. When blood glucose levels are well outside physiological ranges (e.g. >11 mmol.L-1 
[14]) the scan should be postponed. We use a stricter cut-off for research purposes (8.0 mmol.L-1). 
 
1.1.2 Uptake period 
Typically, PET acquisition is performed 45-60 minutes after FDG injection, based on the fact that FDG activity 
concentrations become constant within the first hour after tracer injection in normal tissues. In malignancies, 
however, it has been shown that for some tumour types FDG concentration continues to increase up to four-five 
hours after injection and that constant FDG activity concentrations are rarely reached within the first hour after 
injection. Between 60 and 90 min post-injection, it is not uncommon for a lesion to further increase SUV as 
much as one tenth of the value reached 10 h post-injection [23]. Since a further increase in FDG activity 
concentration one hour after injection is rare in normal tissues [24], it has been hypothesized that dual time-point 
imaging (45 and 90 min post-injection) might improve detection rates of lesions with high glucose metabolism 
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by increasing tumour-to-background ratios. Therefore, for response monitoring studies using SUVs it is highly 
important to keep the uptake period of FDG within narrow limits (55-65 min) [13, 14]. 
 
1.1.3 FDG distribution and clearance 
To optimize the distribution of FDG throughout the body, international guidelines recommend prehydration (0.5 
L) of the patient to ensure excretion of FDG from healthy background tissue, which may be further enhanced by 
furosemide-induced forced diuresis. This might be of special value when the pelvis or kidney regions are of 
interest [12-14]. Median SUV values of tumours are lower in case furosemide is used. However, the total 
fraction of excreted activity is not different in case diuretics are used, but is significantly higher early after 
injection for the furosemide group leading to improved image quality and reducing patient radiation exposure 
[25]. Therefore, it seems important when comparing parameters for glucose metabolism that the use of (loop) 
diuretics should be taken into account. A practical disadvantage of using forced diuresis during dynamic 
acquisition is that measures should be taken to avoid premature termination of the acquisition due to urinary 
urgency. 
 
1.1.4 Patient (periodic) motion 
Apart from exercise-induced increased muscle uptake during the uptake period, the effect of motion during 
acquisition has consequences for lesion localization (e.g. spatial mismatch around the diaphragm due to 
breathing) and causes smearing of the lesion activity concentration within the volume of movement. 
Consequently, the lesion metabolic volume is overestimated and the SUV is underestimated. Moreover, tissue 
inhomogeneity is similarly smeared, leading to loss of spatial heterogeneity. The magnitude of the decrease of 
recovered activity concentrations depends most markedly on lesion size and amplitude of motion and to lesser 
extent to the motion frequency. Recovered activity concentrations can be increased by better lesion volume 
estimation by a motion-correction algorithm. Verified in nine lung cancer patients, this algorithm reduces the 
estimated lesion volume by 15% leading to an increase of the mean SUV in the ROI (SUVmean) by 5% [26]. 
Different other techniques may be applied to improve recovery of activity concentration in periodically moving 
lesions such as gated-PET/CT (in which data is only acquired during a certain respiratory phase), respiratory 
correlated dynamic PET/CT (by summing the sinograms of images of a particular breathing phase selected using 
a point source) or deep inspiration breath-hold PET/CT [27]. 
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During dynamic acquisition, non-periodic patient movement can have major influence on measured 
parameters, since the lesion can “move into” the ROI usually defined in the last time frame(s). Consequently, 
activity concentrations of the lesion are underestimated for the period before patient movement due to a 
mispositioned ROI. In the time frames in which the lesion of interest is visible the ROI can be realigned, but 
during the early time frames this is often impossible due to noisy images or insufficient tissue-to-blood contrast. 
Patient movement therefore should be prevented and monitored during acquisition, the original position should 
be restored as quickly as possible and any movement should be noted including time at which it occurred. 
In case CT-based attenuation correction (AC) is used, any spatial mismatch will lead to incorrect 
amplification of measured activity concentrations, leading to unreliable values for lesion quantification 
(differences of around 10% in SUV [28, 29] due to breathing, smallest for free breathing CT [28]). 
 
1.1.5 Patient discomfort 
Patient stress or cold during the distribution period increases uptake of FDG in muscle and brown adipose tissue 
(BAT) [30-32]. This can lower detection sensitivity (by lowering contrast) and specificity (by increasing the 
number of false positive lesions) of the images and might affect quantification [14, 33]. Factors known to 
increase FDG uptake in BAT such as exposure to cold [31, 32, 34-36] should be prevented by exposing patients 
to thermoneutral conditions. Medication such as the beta-adrenergic blocking agent propranolol [31, 36-39], 
reserpine [36], the opiate fentanyl [40] all prevent FDG uptake in BAT, but the effect of benzodiazepines seems 
doubtful [35, 36, 40, 41]. The NEDPAS guidelines [14] suggest considering the use of benzodiazepines to 
reduce muscle uptake when tumours in the head and neck region are expected and state that there is no place for 
it to reduce uptake in BAT. 
 
1.2 Technical factors affecting quantification 
At the time of data acquisition, several factors influence quantification. These include scan acquisition 
parameters (such as acquisition mode, scan duration, bed overlap and administered FDG activity), time frame-
duration in dynamic acquisitions, factors related to attenuation correction (such as motion and the use of CT 
contrast agents) and other forms of data correction. Most of these settings are based on the performance of the 
scanner and should be measured according to the NEMA (National Electrical Manufacturers Association) NU2–
2007 standard [42] (table 2). 
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1.2.1 Acquisition parameters 
The choice of acquisition parameters are closely interrelated and are based on trade-offs between signal-to-noise 
ratio (SNR) and radiation safety, financial issues (e.g. patient throughput, costs of FDG), patient comfort and 
logistics. Increasing the sensitivity of the PET-scanner by using 3D acquisition (instead of 2D acquisition using 
lead or tungsten septa between crystal rings), increasing scan duration, enlarging bed-overlap and raising the 
administered FDG activity (below the amount that results in count rates exceeding the maximum count rate 
capabilities of the scanner) all improve SNR. Removing the interplane septa from the PET scanner (i.e. changing 
from 2D to 3D mode) typically leads to a four- to eightfold increase in sensitivity but also increases the number 
of detected scattered and random photons. Generally, the peak noise equivalent count rate (NEC) is obtained at a 
lower activity concentration in 3D than in 2D as expected from the behaviour of the (increased) true coincidence 
rate. As a result the SNR (for a uniform cylinder NECSNR ∝  [43]) will be higher when operating in 3D 
versus 2D mode for the low activity concentration range. Recommendations for administered FDG activity 
therefore should be based on acquisition mode (2D or 3D), scan duration and bed-overlap, rather than on pre-
determined diagnostic reference levels [12]. The NCI guidelines recommend a total administered FDG activity 
of 5.18-7.77 MBq·kg-1 [13], the NEDPAS recommendations advise 27.5 MBq·min·kg-1 (for 2D and ≤25% bed-
overlap), 13.8 MBq·min·kg-1 (for 3D and ≤25% bed-overlap) or 6.9 MBq·min·kg-1 (for 3D and 50% bed-
overlap). For a 3D acquisition of a 70kg patient with 4 min per bed position (with 25% bed-overlap), it 
recommends approximately 242 MBq (±10%) to be administered, which corresponds to an effective absorbed 
dose of 4.6 mSv of the FDG (0.019 mSv·MBq-1 [44]). Reducing scan duration therefore necessitates increased 
administered FDG activity to maintain SNR. Increasing acquisition time effectively maintains the quality (SNR) 
of FDG-PET scans of heavier patients, agreeing with the hypothesis that increasing bodyweight increases the 
fractions of random and scatter coincidences [45, 46]. Increasing administered FDG activity does not improve 
SNR in a study, explained by the fact that it was likely to saturate count rates of the equipment [47]. 
 
1.2.2 Time frame-duration 
For dynamic acquisition, activity concentration changes are largest during the first minutes of acquisition (bolus 
transit) but depend on the rate of FDG infusion, distribution and clearance. Therefore, when partitioning 
listmode data or using pre-defined time frames, one should consider a high temporal resolution for this period, 
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especially important for pharmacokinetic analysis of 2-compartment models. Improvement of temporal 
resolution inherently decreases the count accuracy per time frame, since the (approximate) Poisson distribution 
of count statistics (for prompt coincidences) dictates a relative standard deviation dependent on the inverse 
square root of the observed counts. As the choice of framing and the duration of FDG infusion are related, it is 
impossible to give general recommendations. Generally, for scanners with low sensitivity, time frame durations 
should be longer and consequently the rate of FDG infusion slower. The choices of different groups using 
dynamic acquisition for oncological purposes can be found elsewhere [48-50] (figure 1). 
 
1.2.3 Attenuation Correction 
Correction for photon attenuation is necessary since positron annihilation photons interact with surrounding 
tissues (mainly Compton scattering, in lesser extend photoelectric effect). Before the introduction of combined 
PET/CT, attenuation correction was applied by transmission imaging of the subject with an external rotating 
isotope source, either positron-emitters (e.g. 68Ga using its mother isotope 68Ge) or single photon emitters (e.g. 
57Co or 137mBa using its mother isotope 137Cs). Since photon attenuation is dependent on the photon energy, the 
latter two require scaling to obtain transmission sinograms adapted to 511 keV photons. The attenuation 
sinogram, the ratio of a transmission scan and a scan without an object in the FOV (blank scan), is used to 
correct the emission sinogram, which is subsequently reconstructed to an image. Since the introduction of the 
PET/CT, the spatial distribution of the linear attenuation coefficients can be obtained using the CT-scanner. 
Advantages of CT-AC are: reduction in total scan time, lower noise in the transmission sinograms and no 
replacement of isotope sources necessary due to decay. Finally, they can be acquired after tracer injection, 
choosing the energy window around the CT photon peak to exclude the 511 keV photons (radionuclide-based 
transmission scans suffer from contamination by emission photons unless the transmission data are acquired 
before the PET tracer is administered to the patient). CT-AC however leads to extra challenges: the use of 
polyenergetic Bremsstrahlung photons with energy much lower than 511 keV (X-ray tube potential difference 
usually~130 kV leading to photon-energy ranging 40-130 keV, effective energy ~70-80keV), artefacts due to 
spatial mismatches with PET or metal objects, effects of CT-enhancing contrast and artefacts due to truncation 
and beam-hardening [51]. 
Conversion of the X-ray to 511 keV linear attenuation coefficients can be performed by either 
segmentation, scaling or dual X-ray imaging. By segmentation, regions of different material types are identified 
for which linear attenuation coefficients for 511 keV photons are known. Linear scaling of X-ray linear 
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attenuation coefficients can be performed as long as Compton scattering is the major determinant of attenuation. 
However, at CT photon-energies the photoelectric effect plays a significant role for high atomic number 
elements (e.g. calcium in bone, iodine or barium in contrast agents with atomic numbers of 20, 53 and 56, 
respectively) in which case hybrid or bilinear scaling is appropriate [51]. Finally, linear attenuation coefficients 
can be measured at two tube potential differences, enabling the separation of attenuation due to the Compton 
scattering and the photoelectric effect. In practice, no significant difference in quantification of malignant lesions 
is found comparing CT-based attenuation correction with segmented AC (SAC) using transmission imaging [28] 
or between measured (MAC) and segmented (SAC) attenuation correction using transmission imaging [29] 
CT-artefacts due to metal objects and attenuation due to iodine-containing CT-contrast agents might 
influence lesion quantification. Multiple studies have found a negligible change of the SUV in a variety of 
malignancies varying from +2.8% to +4% [52-55]. This small effect surprisingly disappears after chemotherapy 
[52]. The SUVmean significantly increases in the (normal) aorta (+15%), kidneys (+13%), liver (+11%), spleen 
(+10%) and inferior caval vein (+12%) [52]. This might be of relevance when the plasma time-activity 
concentration curve for pharmacokinetic analysis is image-derived (IDIF): a positive bias in the input function 
leads to underestimation of MRglc. Around metal prosthesis, CT-AC leads to an underestimation of FDG activity 
concentration by <6% [28]. 
Finally, truncation artefacts, due to a smaller transaxial FOV of CT than that of PET, lead to incorrect 
attenuation correction in case there are tissues outside the CT FOV. Therefore it is recommended to scan a 
patient with arms up except for head and neck imaging. Usually the degree of truncation is small and therefore 
no major effects on quantification are expected. Lowering the arms also causes beam-hardening (structures of 
higher density cause attenuation of low-energy photons of the polyenergetic X-ray bundle) and scatter-induced 
artefacts. These can influence quantification up to 11-15% [51]. 
 
1.2.4 Other data corrections 
Apart from attenuation correction, other corrections must be applied before an image can be quantified. These 
are: normalization, correction for random coincidences, correction for scattered radiation, correction for dead 
time and cross calibration with a dose calibrator or well counter. 
Remaining differences in detection sensitivity that have not been corrected in the setup procedure are 
corrected by normalization. During normalization all detectors are exposed to the same amount of radiation by a 
rotating source or a cylinder with a uniform activity concentration. The measured counts of each detector pair 
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(line of response, LOR), which should all be equal, are corrected by normalization factors, which are used to 
scale the number of counts of each detector pair to correct the emission sinogram. Using 3D acquisition poses 
this to a new challenge, since the number of LORs are high (order of 108) therefore to obtain enough counts per 
LOR long normalization procedures seem necessary. For this reason modified methods have been developed. 
Instead of using the acquired number of counts in each LOR separately, a factorization into different components 
is being made (component-based normalization). These components are the individual crystal detection 
efficiencies, geometrical factors which account for differences in the distance between detectors and their 
exposed face and the position of crystals in a detector block [56, 57]. 
Random coincidences arise when photons of two unrelated positron annihilations are detected within the 
coincidence timing window and are recorded as a single pair. This leads to incorrectly positioned LORs and thus 
adds a relatively uniform background to the reconstructed images. An estimate of the random coincidence rate 
can be obtained by delaying the coincidence timing window by an interval relatively large to its width. Delayed 
coincidences cannot be true or scattered events, since photons of the same positron annihilation will always be 
detected within a few nanoseconds of each other, but the rate of random coincidences will be the same in the 
delayed and the original window. This number can be subtracted real-time from the total number of coincidences 
for the detector pair to correct for randoms. This, however, will increase the statistical noise-level of the 
corrected images, since the variance of the number of random counts is added to the variance of the uncorrected 
counts. Other methods use ‘smoothed-delays’, in which the delayed coincidences are acquired in a separate and 
thereafter smoothed sinogram, or estimations based on singles rates [58]. 
One or both photons arising from one positron annihilation might be Compton scattered by the tissue within 
the gantry, leading to mispositioned LORs. This leads to a hazy background activity concentration, generally 
highest in the centre of the image. The percentage of scattered events detected in 3D PET might approach 60-
70% of all coincidences. The attenuation data can be used to estimate the number of scattered photons as for 511 
keV photons virtually all attenuation is due to the Compton-effect [51]. Another method is by extrapolation of 
the projection profiles immediately outside the object (determined from the attenuation data), which only 
represent scattered photons as almost no positron annihilations occur in air. This scatter distribution profile can 
be subtracted from the projections prior to image reconstruction [59]. A study of cerebral FDG-PET describes 
that all the pharmacokinetic rate constants of glucose metabolism are overestimated due to photon scatter up to 
10-30% (in decreasing magnitude: K1, Ki, k2, k3 and k4). MRglc is 12-30% higher when no scatter correction is 
applied [60]. 
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At high count rates effects of system recovery after detection of a photon are piled-up leading to dead time. 
Systems can either be nonparalysable (i.e. any event within the dead time will not be counted) or paralysable (i.e. 
this event will furthermore restart the dead time). Empirical dead time models can be used in which the observed 
count rate as a function of radioactivity concentration is measured for a range of object sizes at different energy 
window widths, but other methods are under investigation [61].  
If all previously mentioned corrections are applied, the number of counts per voxel in the reconstructed 
images is directly proportional to the activity concentration of that voxel. Calibration to absolute concentrations 
can be performed by scanning e.g. a cylinder containing a uniform solution of known activity concentration. The 
obtained calibration factor can be used for absolute quantification of the images. 
 
It can be concluded that standardization of PET acquisition is highly important. Images should be acquired in a 
normoglycemic (fasted) state. When using insulin to reverse hyperglycaemia, this should be injected at least but 
preferably longer than one hour before the FDG. The distribution period should be held within narrow limits (55-
65 min). The effect of prehydration and diuretics led to recommendations advocating standardization. For 
dynamic acquisition, however, the practicability of forced diuresis should be considered. Patient motion leads to 
underestimation in the measured SUV or MRglc and should therefore be prevented. To prevent muscle uptake 
and uptake in BAT, the waiting room should be kept warm and the patient should be instructed to minimize 
exercise. The effect of benzodiazepines is doubtful and recent literature suggests the use of beta-blocking agents 
when uptake in BAT is interfering interpretation of the images. 
The administered FDG activity should be standardized, dependent on acquisition method and patient 
bodyweight and kept within narrow limits (<10%). When using CT-attenuation correction, quantification in 
areas around (metal) artefacts should not be performed. Likewise, quantification of lesions in case of spatial 
mismatch between PET and CT should not be performed. Even thought the effect of contrast-agents on SUV 
may be small, the bias introduced in the blood pool used for pharmacokinetic modelling is large and is therefore 
its use is discouraged. Whenever possible, acquisition should be performed with the arms outside the FOV to 
prevent effects of truncation, beam-hardening and increased photon scattering. For reliable quantification, the 
scanner should be normalized, (cross-) calibrated and corrections for photon attenuation, randoms, scatter and 
dead time should be performed. 
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2 Tomographic reconstruction 
Analytical algorithms (e.g. filtered backprojection, FBP) are almost completely replaced by iterative statistical 
algorithms (e.g. Ordered Subset Expectation Maximization, OSEM) for tomographic reconstruction of acquired 
coincidence events to quantifiable images. Iterative reconstruction has a number of potential advantages that 
make it attractive in comparison with analytical methods. Analytical algorithms have the intrinsic, limiting 
assumption that measured data are perfectly consistent with the object, which is never true in practice due to 
noise and other physical factors (e.g. attenuation). In contrast, iterative algorithms can incorporate a priori 
information such as the statistical distribution of the coincidences and position dependent spatial resolution. 
Important adjustable parameters for tomographic reconstruction are the matrix size (the number of voxels in the 
transaxial plane of the reconstructed images) and the reconstruction smoothing filter. For iterative algorithms 
also the number of iterations (the number of times the estimate of the real object is updated) and the number of 
subsets (the number of projections updated simultaneously in each iteration, in OSEM iterative reconstruction 
only), need to be defined. 
 
2.1 Analytical versus iterative reconstruction 
Studies comparing the difference of FBP to OSEM on quantification of glucose metabolism [62-64] all report 
higher SUVs for OSEM as compared to FBP. This might not only be due to the reconstruction algorithm but also 
caused by different attenuation correction techniques (SAC with OSEM vs. MAC with FBP) and by different 
reconstruction filters used [63, 64]. Similar [65] or slightly lower (2.3%) [66] SUVsmean for different tissues are 
found in OSEM compared to FBP, using the same method of attenuation correction. This negligible effect might 
be due to the higher noise-levels in FBP-reconstructed images, leading to different ROIs defined on FBP 
compared to OSEM reconstructed images: when the same ROIs are used on both images, no significant 
differences are found [11]. Apart from noise, also a difference in resolution may cause the dissimilarity in 
quantification: higher uptake values and MRglc are found in tumours (+14%), brain (+2 to +4%) and heart (+15 
to +21%) for OSEM than for FBP, which is almost completely reversible by equalizing the image resolution by 
smoothing with a 5 mm FWHM Gaussian kernel [67]. 
When specifically looking at the IDIF of the left ventricle and ascending aorta, good agreement between 
OSEM and FBP is observed for the first five minutes of the scan, but for the last 30 minutes of a 1-hour scan, 
OSEM-derived IDIFs result in 30% higher activity concentrations for the ascending aorta compared to those 
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derived by FBP [67]. It was concluded that OSEM causes bias in regions located within a hotter background, 
especially relevant for determination of an IDIF. Activity concentrations of IDIFs in the ascending or descending 
aorta of FBP reconstructed images are within 5% of the arterially sampled, leading to similar results for Patlak 
MRglc using either this IDIF or arterial sampling [48, 68]. 
 
 
2.2 Parameters of iterative reconstruction  
The number of subsets has only a small effect on the SUV in phantom experiments when the product of 
iterations and subsets is kept constant. A low number of iterations (1 or 2) results in poor recovery of tumour 
activity concentrations. Further increase of the number of iterations does not improve the accuracy of 
quantification of glucose metabolism of lesions with an SUV higher than 5, but mainly results in an increase of 
image noise. When the SUV is lower than 5, large variability in SUV is seen as a function of the number of 
iterations [29]. In a study of 50 oncological patients, the SUVmean in images reconstructed with 28 subsets and a 
varying number of iterations was systematically increased. This effect was very small after 5 iterations (<1% 
change between 5 and 40 iterations) [7]. 
Image matrix size influences both noise (smaller number of counts per voxel in larger matrices) and spatial 
resolution in phantom experiments [8]. The recovery of the activity concentration in the spheres of a phantom is 
better when the matrix size is increased from 128·128 (voxel size ~5·5 mm) to 256·256 (voxel size voxels 
~2.5·2.5 mm). This dependency is smaller when the smoothing kernel is larger (8 vs. 5 mm full-width at half 
maximum, FWHM). This can be explained since the image resolution (5 or 8 mm FWHM) is not at least twice 
the size of the voxel size (violation of the Nyquist principle) which can be solved by increasing the matrix to 
256·256. 
 
It can be concluded that iterative reconstruction can be used for quantification in oncology. For pharmacokinetic 
analysis of 2-compartment models, the IDIF of the left ventricle seems to be sensitive to spill-in and the use of 
the aorta is preferred. Care should be taken not to overiterate, which only adds noise, which is especially 
cumbersome in pharmacokinetic rate constant estimation. Too few iterations however will lead to loss of high-
spatial frequency features, such as resolution and heterogeneity. The matrix size should be chosen not to violate 
the Nyquist criterion.  
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3 ROI definition 
FDG uptake or metabolism is determined in an ROI, which can be the hottest voxel within the lesion (ROImax), 
but can also be based on an absolute threshold (e.g. an SUV value of 4.0: ROI4.0), on a relative threshold (e.g. 
>50% of maximum voxel value within the ROI: ROI50%), on a manually placed fixed volume (e.g. 1 mL sphere: 
ROIsphere:1mL) or adaptive (e.g. Relative Threshold Level: ROIRTL). Further refinements can be introduced such as 
applying a relative threshold of the background subtracted maximum voxel value (e.g. >50%·(maximum-
background) above background: ROI50%(B+Max)). The best ROI is dependent on its goal: when used to quantify 
tumour FDG uptake or metabolism, the ROI that yields the best correlation with clinical outcome is preferred. In 
other situations (e.g. radiotherapy target planning), the exact volume and position of the ROI is more important. 
Since all but the fixed volume ROI are dependent on the maximum voxel value, the shape and size of these ROIs 
are dependent on all earlier mentioned factors influencing the SNR. 
The influence of the ROI definition on the accuracy of the SUV was determined in a phantom study 
comparing ROI50%, ROI70%, ROI50%(B+max), ROImax and ROIsquare15mm [8]. As expected, the recovery coefficient 
increases for all ROI definitions as a function of the lesion size. There is a strong dependency of SUV on SNR, 
with a high SNR leading towards a positive bias for the maximum voxel value and thus overestimation of SUVs 
calculated with an ROI dependent on this maximum voxel value (all but ROIsquare15mm). The effects of the ROI 
method on the accuracy of SUV determination are trivial: ROI70% and ROI50% are about 15% and 30% lower 
than ROImax respectively and ROI50%(B+max) is in between: close to ROI50% for high tumour-to-background ratios 
and close to ROI70% for a low tumour-to-background ratio. Overall, ROI50% seems to be most accurate for high-
resolution (noisy) data and ROImax seems to be most accurate for smoothed (low-noise) data. The fixed volume 
ROI (ROIsquare:15mm) performs worst since it includes a significant number of non-tumour voxels, especially in 
smaller lesions [8].  
In an ROI definition study of response assessment of lung cancer comparing ROImanual, ROImax, 
ROIcircle:15mm, ROI75% and ROI50% it is mentioned that ROIs50% in lesions with low uptake are often discarded on 
post-chemotherapy scans because of inclusion of non-tumour tissue [11]. Nevertheless, an excellent test-retest 
reproducibility of the volume of ROI50% on 2 consecutive days is reported (ICC=0.99). The fixed volume based 
ROI (ROIcircle:15mm) shows best reproducibility with respect to SUVmean (ICC=0.95) but the reproducibility of 
ROI50% is also very high (ICC=0.91). 
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Due to the partial-volume effect (PVE [69]), the isocontour level for proper whole-lesion delineation is 
lesion size-dependent. Previously, in phantom measurements the exponential relation between lesion volume and 
threshold (percentage of maximum value) was determined for 5 different contrast levels and used on metastatic 
lung lesions yielding highly correlated ROI- and CT-volumes (correlation coefficient: 0.999) [70]. A more 
sophisticated approach was promoted later in which a 3D sphere was convolved with a symmetric trivariate 
Gaussian point-spread function [71]. This equation for background-subtracted relative threshold level (RTL) as a 
function of tumour radius and image resolution, is independent of the tumour-to-background ratio and is used 
iteratively on PET-data until the measured PET-volume and threshold match. In patients the technique seems 
feasible and similar dimensions are achieved as pathologic examination of liver metastases. 
 
In conclusion, a number of methods for definition of the region of interest are described in literature. The 
maximum voxel value is preferable in data with limited noise, does not require specialized algorithms and does 
not suffer from interobserver variability. A threshold-based ROI can provide reproducible quantification of 
glucose metabolism with better accuracy in noisy images. The NEDPAS guidelines recommend the use of an 
ROI41%(B+max), but to increase the (background corrected) threshold when no meaningful tumour volume 
definitions are provided in lesions with a low signal-to-background ratio. They stress that the maximal voxel 
value should always be noted [14].  
 
4 Quantification 
Quantification of FDG uptake or metabolism of the tissue within the ROI can be performed on several levels of 
complexity: semiquantitatively or quantitatively (from dynamic FDG-PET acquisitions) using pharmacokinetic 
analysis of 2-compartment models. 
 
4.1 Semiquantitative methods 
The simplest method to quantify tracer uptake is by calculating tumour-to-non-tumour ratios (T/N) using a 
reference tissue, which may be difficult to define or may have limited uptake (resulting in a relatively high noise 
level). Furthermore, uptake in this reference tissue may be influenced by factors such as therapy, and therefore 
T/N ratios can change without change in tumour biology. 
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Since tracer-uptake is directly related to body volume of the patient and the AA present in the subject at 
start time of the scan, measured uptake (Bq·cm-3) should be normalized for these factors. This results in an SUV 
and is in older papers being referred to as differential absorption (or uptake) ratio (DAR, DUR). The least 
complicated normalization is by AA and patient bodyweight (SUVBW). For uniform tracer distribution the SUV 
is 1.0 and an SUV>1 implies tracer accumulation. As sceptically reviewed by Keyes Jr. [72], body composition 
and habitus are a source of variability since fat has a much lower uptake of FDG than other tissues. Therefore 
other definitions for volume of distribution of FDG are proposed. It is observed that SUVBW is still positively 
correlated to bodyweight for normal tissues, leading to SUVsBW in heavy weighted patients up to twice that of 
normal patients. However, the SUVLBM is weight-independent [73]. Others [74-76] provide evidence that the 
overestimation of SUVBW of liver tissue in heavy oncological patients can be prevented using BSA (body surface 
area) as normalization factor. See table 3 for definition of various types of SUV. 
Another factor related to SUV, is the plasma glucose level. It is unlikely that the effects of variations in 
glucose level only hold true for hyperglycaemic conditions. The decreased uptake values during hyperglycaemia 
can be adjusted for by normalizing the SUV for plasma glucose divided by the population average (100 mg·L-1 
(≈5.6 mmol·L-1)) [17].The NEDPAS guidelines [14] support a normalization for glucose concentration based on 
plasma glucose concentration [mmol·L-1] divided by the population average (5.0 mmol·L-1). 
 
4.2 Quantitative Measures 
4.2.1 Analysis of 2-compartment models by non-linear regression 
Dynamic PET studies provide the opportunity to perform pharmacokinetic analysis of 2-compartment models of 
glucose metabolism. In addition to the PET signal ( ( )tCPET ), the tracer concentration in the arterial blood plasma 
should also be measured ( ( )tCplasma ) which is a drawback compared to static methods in which only the SUV is 
of interest. Another drawback of dynamic acquisition is that only one FOV (typically ~15-20 cm) can be taken 
into account, therefore in metastasized disease not all lesions can be quantified simultaneously. 
Since deoxyglucose-6-PO4, in contrast to glucose-6-PO4, cannot be catabolized further and does not 
diffuse across cell membranes, metabolism can be simplified to a 2-compartment model (figure 2) with 4 rate 
constants. Tracer kinetic modelling is based on several key assumptions including the tracer principle (i.e. 
negligible concentration of the tracer), steady-state assumption (i.e. metabolic processes are at steady-state 
during measurement), tissue homogeneity and instantaneous mixing assumption (i.e. homogenous tracer 
Page 18 of 35 
 
distribution within each compartment), linearity assumption (i.e. rate constants are independent of tracer 
concentration: first-order kinetics) and the tracerdynamic assumption (i.e. the tracer behaves similarly to the 
substance under investigation) [77]. Moreover, it is assumed that the extraction of FDG from the plasma 
normally is low enough for the delivery of FDG to be independent on blood flow. 
According to the Michaelis-Menten hypothesis, an intermediate complex is formed between the 
substrate (S) and the transporter or enzyme, which is then converted to the chemical product (P) with release of 
the transporter or enzyme. The reaction rates of these processes are described by ( ) 1max ][][ −→ +⋅⋅= mPS KSSVk  
in which Vmax is the maximum rate of the reaction and Km (the Michaelis constant) is that concentration of the 
substrate ([S]) which leads to 0.5·Vmax. This is clearly a nonlinear relation, but linear tracer compartment models 
are still possible to be used in case an alternative substrate (S*) is competing for the transporter/enzyme which 
concentration is of a much lower value than of S [78, 79]. In this case, the reaction rate of the original substrate 
is (approximately) unaltered and the reaction rate of the tracer can be described as: 
( )( ) 1***max** ][][ −→ +⋅⋅⋅⋅≅ mmmPS KSKKSVk  which is a linear function of [S*] as long as ][*][ SS << . Therefore 
the 2-compartment model with 4 pharmacokinetic rate constants (Phelps 4K model) can be expressed by the 
following differential equations [80]: 
( ) ( ) ( ) ( ) ( )tCktCkktCK
dt
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Where ‘⊗ ’ stands for the operation of convolution and ( ) ⎥⎦
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The sum of the activity concentrations in both compartments plus a fraction of the plasma activity concentration 
( ( )tCV plasmab ⋅ , with Vb the blood volume fraction) are measured within the ROI by the dynamic PET 
acquisition: 
( ) ( ) ( ) ( )( ) ( )tCVtCtCVtC plasmabboundfreebPET ⋅++⋅−= 1       Eq. 3. 
 
Page 19 of 35 
 
Therefore, when the plasma input function is known, all five free parameters of FDG metabolism (K1, k2, k3, k4 
and Vb) can be estimated using non-linear least squares fitting of ( )tCPET . 
The original irreversible model (Sokoloff 3K model) did not incorporate k4 [81] since the rate of 
hydrolysis of FDG-6-PO4 by glucose-6-phosphatase activity is negligible in mammalian tissues, except for liver 
tissue [82]. This is verified in further studies [83], which compare the residual sum of squares of fits with and 
without k4 by the Akaike Information Criterion [84] and Schwarz–Criterion [85]. These statistics reward 
goodness-of-fit but depreciate the number of free parameters of the model (the lowest value denotes the model 
that best explains the data with a minimum of free parameters). Moreover, simulation studies caution that a k4 
might result from tissue heterogeneity rather than real dephosphorylation [86]. Therefore currently most studies 
use the simplified 3-rate constant (Sokoloff 3K) model. With k4=0, equations 1 and 2 simplify to: 
( ) ( ) ( ) ( ) ( ) ( ) ( )tCeKtCtCkktCK
dt
tdC
plasma
tkk
freefreeplasma
free ⊗⋅=⇒⋅+−⋅= ⋅+− 321321    Eq. 4. 
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The ratio of the phosphorylation rates of FDG (MRFDG) and glucose (MRglc) equals both the ratio of fluxes 
between the compartments of free and bound substrates (equation 5) and the ratio of the Vmax, Km and 
concentration of both the intracellular free tracer and the natural substrate: 
( )
( )
( )
( )tCKV
tCKV
tCk
tCk
MR
MR
glcfreeFDGmglc
FDGfreeglcmFDG
glcfreeglc
FDGfreeFDG
glc
FDG
,,max,
,,max,
,,3
,,3
⋅⋅
⋅⋅
=
⋅
⋅
=      Eq. 6.
 
In contrast to analogue tracers (such as FDG) when direct isotopic substitution labelling of glucose is used (e.g. 
[11C]-glucose), the Vmax and Km for both substrates are essentially the same equation 6 would reduce to a simple 
ratio of concentrations of FDG and glucose. In the condition where )(tCplasma  of glucose and FDG is constant, 
equation 6 can be written as: 
( )
( ) FDGglcFDGmglc
FDGglcmFDG
glcplasmaglc
FDGplasmaFDG LC
KV
KV
FCMR
FCMR
=
⋅⋅
⋅⋅
=
⋅⋅
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−
−
λ
λ
,max,
,max,
1
,
1
,      Eq. 7
 
In which F is the blood flow and λ are the partition coefficients ( 1−⋅ plasmafree CC ) of both the substrates. This ratio 
is called the lumped constant of FDG (LCFDG), or the steady-state ratio of the net extraction of FDG to that of 
glucose at constant plasma levels of both substrates [81]. The full operational equation is often written as: 
( ) 1,max,,max, −⋅⋅⋅⋅⋅= φλ FDGmglcglcmFDGFDG KVKVLC . In this λ denotes the ratio of partition coefficients and φ is the 
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fraction of glucose-6-PO4 that continues down the Embden-Meyerhof pathway (i.e. regular glycolysis), which is 
normally quite close to 1.0. The value of the LCFDG can be determined by simultaneous measurement of MRglc 
(e.g. by [11C]-1-glucose) and MRFDG [87], independent determination of all six parameters of the LC or by the 
ratio of fractional arteriovenous differences for the two substrates [81, 88]. 
In the steady state condition of the compartment of free intracellular FDG, the flux into this 
compartment is balanced by the flux out ( ( ) 0)( 1 =⋅ −
FDGfree
dttdC ), the MRglc can be estimated from equation 5 
and 7: 
FDG
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In a study with 20 patients with non-small cell lung carcinoma using the Sokoloff (3K) model, it was shown that 
parameter estimation by non-linear least squares fitting of 30 min dynamic data yielded essentially the same 
results for K1, k2, k3 and Ki, (R2=0.918, 0.937, 0.785 and 0.924 respectively with mean relative differences 
varying 9-25%) compared to a 60 min protocol [89]. 
Primary, glucose metabolism (and thus the LCFDG) are determined in the normal (rat) brain [18, 78, 87]. 
In this field it has been shown that the use of a single LCFDG suits only considering the conditions during which it 
was determined. The LCFDG is dependent on the time between tracer injection and measurement, surely changes 
in any disease with an enzymatic component, probably varies with regional glucose concentrations and in 
conditions of ischaemia, hypoglycaemia, the method of anaesthesia, age (adult or developing) and species of the 
subject under investigation. Due to the heterogeneity of neoplasia, these limitations are far greater and for many 
tumours the LCFDG is not known. As perfectly summarized elsewhere, calculations of MRFDG can be used if one 
is interested in comparative measurements (e.g. metabolic changes over time, during treatment, between a 
diseased or normal tissue or between different physiologic states), assuming the LCFDG of the tissue under 
investigation remains unchanged. In cases in which the true MRglc needs to be determined from FDG results, 
then one must measure the LCFDG in the particular experimental setup [18]. Studies of the LCFDG in oncology are 
very limited and reports of determination of the LCFDG of non-glioma malignant tissues are lacking to this date. 
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4.2.2 Patlak graphical method 
Patlak et al. [90] derived a graphical method (often called Patlak-analysis, Patlak-Rutland or Gjedde-Patlak plot) 
that uses linear regression to analyze pharmacokinetics described by any compartment model with at least one 
irreversible transport-step or reaction (‘trapping’ of FDG due to k4=0 min-1). It further assumes that all the 
reversible compartments must be in equilibrium with the plasma, which in practice only occurs when 
dttdCplasma )(  is small enough for these tissue compartments to follow. Combining equations 3-5, with 
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Linear regression of the plot 1)()( −⋅ tCtC plasmaPET  vs. 
1
0
)()( −⋅∫ tCdC plasma
t
plasma ττ  (“Patlak space” or “Funny 
time”) results in slope: )1( bi VK −⋅ , from which, with an estimated Vb, MRglc can be computed. Simplification of 
the problem of solving differential equations by non-linear optimization to an approach amenable to linear 
regression avoids many problems inherent in the former approach: sensitivity to noise in the time-activity 
concentration curves, parameter covariance, local minima in the approximate solution to the differential 
equations and dependence of parameter estimates on starting guesses. As trade-off only the Ki, but not the 
individual kinetic parameters is estimated. An example is provided in figure 3. 
Linearity in Patlak space is reached in conditions where the plasma FDG concentration is constant, but 
since )(tCplasma  continues to decrease due to irreversible cellular uptake and renal clearance, this situation is 
never fully met. In good approximation, onset of linearity is usually attained 10-15 min after the bolus injection. 
It is shown that MRglc determined by Patlak-analysis over different intervals is highly similar compared to the 
Sokoloff (3K) model (all R2≥0.951). ROIs were defined on the last 3 time frames (45-60 min), which is a 
limitation of this study; in shortened protocols, tumour ROIs have to be drawn at earlier time-points, in which 
the contrast is lower, leading to different ROIs which likely will produce less accurate MRglc [83]. Another way 
of shortening acquisition duration is by combination of an initial 10 min dynamic scan with a single static time 
frame 56-60 min after tracer injection [91]. Highly similar values for Ki between full dynamic and a shortened 
dynamic acquisition are described (R2 of non-linear regression = 0.815). In practice the ROIs need to be 
repositioned since the patient leaves the gantry between both acquisitions. 
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4.2.3 Adaptations to pharmacokinetic models 
Variations to the previously mentioned pharmacokinetic models have been reported frequently [92-98]. A 
variation to the Sokoloff 3K model with 6 parameters uses a reference region outside tumour to account for the 
normal tissue within the tumour ROI (2 ROIs 6P model). In simulation studies it was found to adequately 
describe tumour pharmacokinetic rate constants of 2-compartment models regardless the amount of normal 
tissue within the ROI. A drawback of the technique is that reference tissue must be available [92]. 
Many variations to the Patlak graphical method are reported [93-98]. Wong et al. [93] describe a 
technique in which they create three sequential images (each 15 min duration) starting 10 min after FDG 
injection combined with three arterialized venous samples taken at the mid-time of each scan. This method pre-
empts the need for continues sampling and showed Ki to be within 3-4% of the values obtained by regular Patlak 
analysis. Another variation computes lesion Ki from the mean of the per voxel Ki for which the correlation 
coefficient of the Patlak-plot is above a threshold [94]. This technique was further adapted by defining a 2D ROI 
on a summed image of all correlation coefficient-constrained planes containing the lesion. This ROI was 
propagated over the planes containing the lesion in which the parameters of interest were determined. The 
authors conclude that this technique (Total Lesion Evaluation method, TLE) is less ROI dependent and also 
incorporates therapy-related volume changes and is especially suitable for therapy response monitoring [95]. A 
simplified kinetic method (SKM) is advocated [96], assuming a uniform input function, based on fitting the input 
function of control patients with a tri-exponential decay function. The SKM allows MRglc to be calculated from a 
static image and one late venous blood sample. It was shown in lung cancer patients that the SKM was an 
improvement over the SUV and approaches the MRglc, calculated by non-linear least squares. A hybrid method 
of Patlak and SKM shows less bias and variability than either technique alone. For this method 6 time frames 
(each 5 min, 25-55 min post-injection) are acquired. By using every other time frame (3 data points) or every 
third time frame (2 data points) this method can be used to up to three fields of view [97]. The last method 
mentioned is based on the relation between Ki and SUV, average plasma clearance rate and the initial 
distribution volume of FDG (Sadato method). Estimated Ki and SUV are compared with Patlak Ki, leading to the 
conclusion that the estimated, noninvasively determined Ki is a better indicator of tumour uptake than the SUV 
[98]. 
Hoekstra et al. reviewed [99] and compared [83] 34 variations of previously mentioned methods to 
obtain glucose consumption (2 T/N, 12 SUV, 2 Sadato, 2 SKM, 5 Patlak, 10 TLE and one “2 ROI, 6P” 
variations) on 30 randomly selected dynamic FDG-PET scans in 19 lung cancer patients. Since incorporation of 
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k4 did not improve fits, Sokoloff 3K model was used as gold standard. The reliability of the gold standard was 
considered high since the test-retest variability (ICC=0.95) and intra- and interobserver variability (ICC=0.98 for 
both) were small. Of the 34 models tested, 10 met the required minimal correlation with the gold standard 
(R2>0.95). They concluded that the best simplified options are SUVBSA+glucose (40-60 min or 50-60 min post-
injection), Sadato-method based on BSA and Patlak graphical analysis (10-60 min post-injection). Similarly, 
Lammertsma et al. [100] pooled the results of three studies comparing methodological aspects of response 
monitoring in lung [83], breast [101] and gastro-oesophageal [102] cancer (in total 170 FDG-PET-studies) and 
show excellent correlation with the Sokoloff 3K model of Patlak MRglc (ICC=0.98), SKM (ICC=0.94), 
SUVBSA+glucose (ICC=0.91) and SUVBSA (ICC=0.91). They conclude that although Patlak MRglc has the best 
correlation with the gold standard, it remains to be proved that these findings are of clinical relevance. Changes 
found by SUV estimation may still represent a relevant response [103, 104]. 
 
4.2.4 Input functions 
For all previously described fully quantitative measures of glucose metabolism, the arterial plasma input function 
(IF or ( )tC plasma ) of the tumour should be known. Different approaches to obtain this IF have been described in 
literature. Since it is impossible to sample the artery directly vascularizing the tumour, the gold standard is serial 
arterial sampling of a superficial artery (e.g. the radial artery) after which the activity concentration of the 
plasma, derived by centrifugation can be determined [105]. Alternatives to serial arterial sampling with less 
complications [106] or less radiation burden to the personnel are: (arterialized) venous blood sampling [107], use 
of an IDIF [48, 108], modelling of a population-based IF [109-111] or extraction of IF using mathematical 
segmentation methods [112]. 
To overcome the time-dependent ratio of arterial and venous blood activity concentration, the heated hand 
procedure, that shunts the arterial blood to the venous system, can be performed [107]. In Patlak analysis, the use 
of arterialized venous blood shows a net effect of ~10% overestimation of Ki and ~5% overestimation or MRglc 
compared to the gold standard of arterial sampling. IDIFs of the ascending (ICC=0.98) or abdominal (ICC=0.96) 
aorta shows better Patlak MRglc correlation than IDIFs of the left ventricle (ICC=0.94) [48, 108] but due to the 
PVE the recovery of activity concentrations in the aorta is less than one, causing an underestimation of the FDG 
activity concentration. A left ventricle IDIF shows positive bias, since the PVE caused a hot myocardium to 
spill-in activity in later time frames [48] leading to an underestimation of MRglc of 16.2-17.5% [113]. Another 
drawback of the IDIF is that it is a measure of whole blood activity concentration, which is known to be lower 
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than in plasma and not constant over time [107]. Population based curves reduce the need of blood sampling and 
moreover can be used in body areas where IDIFs are not feasible. They can be based on averaging normalized 
blood curves or on fitting to a proposed equation [109, 110]. Patlak based MRglc obtained by population based 
curves overall show high correlation with the gold standard (R2>0.984) [109]. Usage of mathematical tissue 
segmentation results in whole blood activity concentrations as well [112, 114] but it leads to an image-derived 
whole-blood IF with similar drawbacks as an IDIF. 
For estimation of pharmacokinetic rate constants of 2-compartment models, the exact timing (time delay) 
and shape (dispersion) of the IF are needed. When it is measured by sampling [82], this does not necessarily 
reflect the supply of the tracer to the lesion. The time delay can be corrected for but the dispersion of the IF 
results from the impulse-response characteristics of the distributing system of the patient and is therefore 
difficult to predict [79]. These factors complicate the use of pharmacokinetic analysis of 2-comparment models 
and therefore frequently IDIFs of a large blood pool close to the tumour are used [49, 50]. The effect of time 
delay and dispersion is of negligible relevance for Patlak MRglc estimation, since the )(tCplasma  in the Patlak 
equation is relatively constant in the period of linear regression and the integral of )(tCplasma  is almost not 
affected. 
 
Concluding, for clinical practice and most research into the value of quantification of FDG-PET, the SUVmax and 
SUVs of isocontour based ROIs are most relevant. They can be performed whole-body, pre-empt the need of an 
IF and can be obtained from static images. In special situations FDG metabolism can be quantified using 
dynamic acquisition, preferably using IDIFs of the ascending aorta. Even though these result in absolute 
quantification of FDG influx, they are limited in calculation of ‘real’ MRglc due to the indefinite value of the 
LCFDG. 
 
5 Repeated measures studies 
Quantitative FDG-PET is not only useful as a single-measurement (e.g. for treatment stratification) but repeated 
measurements before, during and after treatment may be used for early response assessment of therapy. For this 
purpose a new quantification parameter is introduced, defined as the product of the SUV and tumour volume 
(total lesion glycolysis, TLG) [115]. Even though the ΔTLG is used in a small number of recent studies [116, 
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117], this response parameter needs further evaluation before it can be recommended for routine use, since it 
does not perform better than ΔSUV alone in all studies [116]. 
Measured tumour response is nearly independent of the ROI definition, since most factors contributing 
to bias and noise cancel out in calculation of the relative change [8, 11]. However, when the tumour volume 
changes significantly, the PVE can play a role which cannot be cancelled by measuring relative effects [8]. For 
matter of reproducibility, threshold based ROIs are recommended for repeated measures studies, with a test-
retest reproducibility of the SUV of 1-13% ±6%-12% [11, 118-120], of Ki of 10%±8% and of K1, k2 and k3 of 
24-42%±13-31% [119]. Due to the magnitude of the day-to-day variation, changes in quantification of SUV 
±15-20% (i.e. 2 standard deviations) are within the reproducibility limits of this method of quantification and 
therefore should be considered as stable values. 
The robustness of variations of the ΔSUV [%] was shown in gastric carcinoma patients neoadjuvantly 
treated with cisplatin-based chemotherapy [10]. The authors conclude that in gastric carcinomas the prediction of 
response to chemotherapy on the basis of relative tumour SUV changes is not essentially influenced by any of 
the methodological variations investigated (incubation period 40 or 90 minutes, reconstruction method FBP or 
OSEM and various SUV normalizations). However, phantom experiments reveal a difference between 
institutions for SUV quantification up to 30%, which can be improved by calibration [29]. This is especially 
important when baseline and follow-up scans are performed in different settings or institutions, underlining the 
need for standardization [14]. 
 
6 Conclusions 
Apart from hardware issues and sources of error, many methodological and biological factors influence 
quantification in FDG-PET. For multicenter investigation therefore these parameters must be standardized and 
intercenter-calibration has to be performed. In general, the relative simplicity of semiquantitative quantification 
by SUV seems to outweigh its drawbacks, providing that the process from acquisition till quantification is 
standardized. Repeated-measures studies seem less dependent on most factors influencing quantification as they 
cancel out in calculation of relative treatment effects providing that the methodology at the baseline scan is 
repeated for the follow-up scan. Pharmacokinetic quantification is a sophisticated and rather complicated method 
and is therefore mainly applied in a research setting.  
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Tables 
Table 1: Commonly used abbreviations 
AA Administered Activity 
AC Attenuation Correction 
BAT Brown Adipose Tissue 
BSA Body Surface Area 
BW Bodyweight 
FBP Filtered Back Projection 
FDG 2-[18F]-2-deoxy-D-glucose 
FOV Field of View 
FWHM Full Width at Half Maximum 
glc Glucose 
ICC Intraclass Correlation Coefficient 
IDIF Image Derived Input Function 
K1 Rate constant of forward transmembranous transport 
k2 Rate constant of reversed transmembranous transport 
k3 Rate constant of cytoplasmic phosphorylation 
k4 Rate constant of cytoplasmic dephosphorylation 
Ki net Influx rate constant 
LBM Lean Body Mass 
LCFDG Lumped Constant of FDG 
LOR Line of Response 
MAC Measured Attenuation Correction 
MR Metabolic (phosphorylation) Rate 
NEC Noise Equivalent Count Rate 
NEMA National Electrical Manufacturers Association 
OSEM Ordered Subsets Expectation Maximization 
PET Positron Emission Tomography 
PVE Partial-Volume Effect 
ROI Region of Interest 
RTL Relative Threshold Level 
SAC Segmented Attenuation Correction 
SNR Signal to Noise Ratio 
SUV Standardized Uptake Value (see table 3) 
Vb Blood Volume fraction 
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Table 2: NEMA properties of currently commercially available modern PET/CT scanners: 
Manufacturer: 
Model 
Crystal 
material: 
Axial FOV: 
[mm] 
Transaxial Spatial 
Resolution:* 
[mm] 
Sensitivity in centre of FOV: 
[cps·kBq-1] 
Peak NEC (1R): 
[kcps] 
General Electric 
Discovery PET/CT 690 [121] 
BGO 157 4.8 6.7 131.1 @ 28.5kBq·cm-3 
Philips 
Gemini TF PET/CT [122] 
LYSO 180 4.8 6.6 125 @ 17.4kBq·cm-3 
Siemens† 
Biograph mCT [123] 
LSO 162 
(218) 
4.2 
(4.1) 
4.5  
(8.1) 
93 @ 34kBq·cm-3 
(161 @ 31kBq·cm-3) 
BSO: Bismuth Germanium Oxide; L(Y)SO: Lutetium (Yttrium) Oxyorthosilicate; NEMA: according to the 
National Electrical Manufacturers Association standard NU 2-2007 [42]; 1R: computed for a noise-free 
estimation of randoms. Other abbreviations are explained in table 1. *average measured FWHM 1 cm from 
centre of the FOV; †the Siemens Biograph mCT has an extension from 3 to 4 detector rings. Properties for this 
extended FOV are given in parenthesis. 
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Table 3: Equations to normalize the SUV 
Bodyweight (BW) 
1000⋅⋅= BW
AA
CSUV FDGBW  
Body Surface Area (BSA) ( )725.0425.016 007184.0]10[ hBW
AA
CmSUV FDGBSA ⋅⋅⋅=
−− † 
 
Lean Body Mass (LBM) Male: 
( )( ) 100015206.10.48 ⋅−⋅+⋅= h
AA
CSUV FDGLBM  
 
Female: 
( )( ) 100015291.05.45 ⋅−⋅+⋅= h
AA
CSUV FDGLBM  
 
Bodyweight and plasma glucose 
1000
0.5
⋅⋅⋅=+ BW
C
AA
C
SUV glcFDGglcBW  
 
Various methods for normalization of FDG uptake for different parameters representing distribution volume. 
AA: administered activity, corrected for decay occurring between time of measurement and start-time of scan in 
Bq; CFDG: average measured FDG activity concentration in region of interest in Bq·cm-3; BW: bodyweight in kg; 
Cglc: glucose concentration in venous plasma in mmol·L-1; h: height in cm; SUV: standardized uptake value in 
g·cm-3 (often SUV is presented dimensionless since it is based on the density of water (ρ=1.0 g·cm-3). SUVBSA 
has a different unit (i.e. 10-6 m-1), therefore it is to be rescaled according to the ratio SUVBW·SUVBSA-1, which is 
3.42·0.083-1=41.2 kg·m-2 in one study [74]) 
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Figures 
Figure 1: Dynamic framing duration in 3 groups [48-50] performing dynamic oncological FDG-PET for 
pharmacokinetic 2-compartment modelling. Abbreviations are explained in table 2. *Duration of a bolus is a few 
seconds. 
 
Figure 2: The 2-compartment model for FDG catabolism. ( )tCplasma : the activity concentration of FDG in the 
blood plasma; ( )tC free : the intracellular activity concentration of free FDG; ( )tCbound : the intracellular activity 
concentration of FDG-6-PO4; K1, k2, k3 and k4: rate constants (see table 1); ( )tCPET : the measured PET-signal 
which is a combination of ( )tC free , ( )tCbound  and a fraction (shaded area, Vb) of ( )tCplasma . The dotted line 
symbolizes the cell-membrane. 
 
Figure 3: Quantitative analysis of a T2 adenocarcinoma of the right superior lung lobe (left-top). Time-activity 
concentration curves (right top). Analysis of 2-compartment models by both Sokoloff 3K and Phelps 4K model 
(left bottom). Patlak graphical analysis (right bottom). 



